Trends in charcateristics, incidence, and outcomes of cutaneous malignant melanoma in Saraburi hospital: A 15-year retrospective study
Article Sidebar
Main Article Content
Abstract
Background: Cutaneous malignant melanoma is a malignant skin tumor that originates from melanocytes. It is one of the aggressive tumors with a significant mortality rate. While the incidence of cutaneous malignant melanoma is increasing worldwide, the mortality rate is decreasing. These interesting trends in incidence and mortality rate may be attributed to improved patients’ knowledge and awareness of cutaneous malignant melanoma, as well as the role of novel therapies such as immune checkpoint inhibitors and targeted therapy. In Thailand, there are few studies that focus on cutaneous malignant melanoma. Objective: To evaluate trends in the characteristics, incidence, and outcomes of cutaneous malignant melanoma at Saraburi Hospital Methods: This is a 15-year retrospective study involving patients diagnosed with melanoma skin cancer. Medical records and pathology databases at Saraburi Hospital were reviewed from January 1, 2008, to July 1, 2023. Results: A total of 50 cases of cutaneous malignant melanoma were found (33 female, 17 male). There was a decreased number of cutaneous malignant melanoma diagnoses during the COVID-19 pandemic with lockdown measures in 2020. There was no significant change in trends in age, most common clinical manifestations (blackish lesion and ulcer), location (lower extremities), type (acral lentiginous), and histological findings (Breslow thickness > 4 mm and Clarke level 4). The 5 year-survival rate was 10% [0.10(0.04-0.20)]. Trends in melanoma staging shows an increasing in stage 3. Conclusions: Trends in the 5-year survival rate show an increased proportion of patients who are alive but a decreased number of patients who died form malignant melanoma.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles in this journal are copyrighted by the Royal Thai Army Medical Department and published under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
may be read and used for academic purposes, such as teaching, research, or citation, with proper credit given to the author and the journal.
Use or modification of the articles is prohibited without permission.
Statements expressed in the articles are solely the opinions of the authors.
Authors are fully responsible for the content and accuracy of their articles.
Any other republication of the articles requires permission from the journal.
References
Wiriyakulsit N, Klomkleang P, Sornda T, Kaewkong W. [Melanoma: Incidence among the Thai population and the use of a molecular understanding of this cancer to improve the strategy of targeted therapy]. Thai Cancer J. 2021;41(3):134–50. Thai.
Zaba L, Wang J, Swetter S. Melanoma. In: Bolognia J, Schaffer JV, Cerroni L, editors. Dermatology Philadelphia. Elsevier; 2024. p. 2009–2044.
Matthews NH, Li WQ, Qureshi AA, Weinstock MA, Cho E. Cutaneous melanoma: Etiology and therapy. In: Ward WH, Farma JM, editors. Cutaneous melanoma. Brisbane; 2017. p. 3–22.
Anothaisatapon K, Meevassana J, Angspatt A. Cutaneous melanoma. In: Chusana Suankratai, editor. MDCU congress 2021: Revolutions in global health. 2021 SEP 8-10 ;Chulalongkornuniversity, Bangkok: 2021 p.489-521. Thai.
Ingkaninanda P, Visessiri Y, Rutnin S. Clinicopathological features and prognostic factors of malignant melanoma: A retrospective analysis of Thai patients in Ramathibodi Hospital. J Med Assoc Thai. 2015;98(8):820–7.
Leeneman B, Schreuder K, Uyl-de Groot CA, van Akkooi ACJ, Haanen JBAG, Wakkee M, et al. Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): A nationwide population-based study. Eur J Cancer. 2021;154:111-19.
Davis CH, Ho J, Greco SH, Koshenkov VP, Vidri RJ, Farma JM, et al. COVID-19 is affecting the presentation and treatment of melanoma patients in the northeastern United States. Ann Surg Oncol. 2022;29(3):1629–35. doi:10.1245/s10434-021-11086-8.
Ungureanu L, Apostu AP, VesaȘtefanC, Cășeriu AE, FrățilăS,Iancu G, et al. Impact of the COVID-19 Pandemic on Melanoma Diagnosis in Romania-Data from Two University Centers. Int J Environ Res Public Health. 2022 ;19(22):15129.
Gil-Pallares P, Figueroa-Silva O, Gil-Pallares ME, Vázquez-Bueno JÁ, Piñeyro-Molina F, Monteagudo B. Did COVID-19 lockdown delay actually worsen melanoma prognosis? An Bras Dermatol. 2023;98(2):176-180.
Sangers TE, Wakkee M, Kramer-Noels EC, Nijsten T, Louwman MWJ, Jaspars EH, et al. Limited impact of COVID-19-related diagnostic delay on cutaneous melanoma and squamous cell carcinoma tumour characteristics: a nationwide pathology registry analysis. Br J Dermatol. 2022;187(2):196–2202. doi:10.1111/bjd.21050.
Ricci F, Fania L, Paradisi A, Di Lella G, Pallotta S, Sobrino L, et al. Delayed melanoma diagnosis in the COVID-19 era: increased breslow thickness in primary melanomas seen after the COVID-19 lockdown. J Eur Acad Dermatol Venereol. 2020;34(12):e778–99. doi: 10.1111/jdv.16874.
Troesch A, Hoellwerth M, Forchhammer S, Del Regno L, Lodde G, Turko P, et al. The impact of the COVID-19 pandemic on the diagnosis of cutaneous melanomas: A retrospective cohort study from five European skin cancer reference centres. J Eur Acad Dermatol Venereol. 2023;37(5):922–31. doi:10.1111/jdv.18953.
Jeremić J, Suđecki B, Radenović K, Mihaljević J, Radosavljević I, Jovanović M, et al. Impact of the COVID-19 pandemic on melanoma diagnosis: Increased Breslow thickness in primary melanomas-A single center experience. Int J Environ Res Public Health. 2022;19(24):16806. doi:10.3390/ijerph192416806.
Lo Bello G, Pini GM, Ferguglia G, Regazzini R, Locatelli A, Patriarca C. Effects of COVID-19 restriction measures and clinical resetting on delayed melanoma diagnosis: a singleinstitution experience. Ital J Dermatol Venereol. 2021;156(4):497-8.
Toma AO, Prodan M, Reddyreddy AR, Seclaman E, Crainiceanu Z, Bloanca V, et al. The Epidemiology of Malignant Melanoma during the First Two Years of the COVID -19 Pandemic: A Systematic Review. Int J Environ Res Public Health. 2022;20(1):305.
Molinier R, Roger A, Genet B, Blom A, Longvert C, Chaplain L, et al. Impact of the French COVID-19 pandemic lockdown on newly diagnosed melanoma delay and severity. J Eur Acad Dermatol Venereol. 2022;36(3):e164–6. doi:10.1111/jdv.17802.
Martinez-Lopez A, Diaz-Calvillo P, Cuenca-Barrales C, Montero-Vilchez T, Sanchez-Diaz M, Buendia-Eisman A, et al. Impact of the COVID-19 pandemic on the diagnosis and prognosis of melanoma. J Clin Med. 2022;11(14):44181. doi:10.3390/jcm11144181.
Lallas A, Kyrgidis A, Manoli SM, Papageorgiou C, Lallas K, Sotiriou E, et al. Delayed skin cancer diagnosis in 2020 because of the COVID-19-related restrictions: Data from an institutional registry. J Am Acad Dermatol. 2021;85(3):721-3.
Weston GK, Jeong HS, Mu EW, Polsky D, Meehan SA. Impact of COVID-19 on melanoma diagnosis. Melanoma Res. 2021;31(3):280-1.
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199- 206.
Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622-34.
Memon A, Bannister P, Rogers I, Sundin J, Al-Ayadhy B, James PW, et al. Changing epidemiology and age-specific incidence of cutaneous malignant melanoma in England: An analysis of the national cancer registration data by age, gender and anatomical site, 1981-2018. Lancet Reg Health Eur. 2021;2:100024.
Lashway SG, Harris RB, Farland LV, O'Rourke MK, Dennis LK. Age and Cohort Trends of Malignant Melanoma in the United States. Cancers (Basel). 2021;13(15):3866.
Liszkay G, Kiss Z, Gyulai R, Oláh J, Holló P, Emri G, et al. Changing Trends in Melanoma Incidence and Decreasing Melanoma Mortality in Hungary Between 2011 and 2019: A Nationwide Epidemiological Study. Front Oncol. 2021;10:612459.
